BRIEF-Knight Therapeutics says received Notice Of Deficiency for its ATryn new drug submission
April 25 (Reuters) - Knight Therapeutics Inc
* Has received a notice of deficiency for its ATryn new drug submission
* Health Canada requested additional technical information on ATryn in order to complete its assessment of product Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
© Thomson Reuters 2017 All rights reserved.